Mannose-guided carrier-free nanodrugs for cascade targeted eradication of intracellular bacterial infections
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Orthopedic Infections and Treatments · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (67)
Show source-provided references
1. Skeletal infections: microbial pathogenesis, immunity and clinical management10.1038/s41579-022-00686-0 ↗
2. Intracellular localisation of mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide10.1038/s41467-021-24127-3 ↗
3. Are bloodstream leukocytes trojan horses for the metastasis of Staphylococcus aureus?10.1038/nrmicro2508 ↗
4. Life on the inside: the intracellular lifestyle of cytosolic bacteria10.1038/nrmicro2112 ↗
5. Intracellular pathogens: living in an extreme environment10.1111/j.1600-065X.2010.01001.x ↗
6. Phagosome–bacteria interactions from the bottom up10.1146/annurev-chembioeng-090920-015024 ↗
7. Immunometabolism at the interface between macrophages and pathogens10.1038/s41577-019-0124-9 ↗
8. Intracellular Staphylococcus aureus perturbs the host cell Ca2+ homeostasis to promote cell death10.1128/mBio.02250-20 ↗
9. Inside job: Staphylococcus aureus host-pathogen interactions10.1016/j.ijmm.2017.11.009 ↗
10. Inability to sustain intraphagolysosomal killing of Staphylococcus aureus predisposes to bacterial persistence in macrophages10.1111/cmi.12485 ↗
11. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the global burden of disease study 201910.1016/S0140-6736(22)02185-7 ↗
12. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 201910.1016/S0140-6736(20)30925-9 ↗
13. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus10.1038/nature16057 ↗
14. Intracellular Staphylococcus aureus persisters upon antibiotic exposure10.1038/s41467-020-15966-7 ↗
15. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages10.1128/AAC.50.3.841-851.2006 ↗
16. Bioinspired drug delivery strategies for repurposing conventional antibiotics against intracellular infections10.1016/j.addr.2021.113948 ↗
17. Antimicrobial effects of fibrous unit in modular self-assembling peptides10.1016/j.nantod.2025.102860 ↗
18. Progress and prospects of nanomaterials against resistant bacteria10.1016/j.jconrel.2022.09.030 ↗
19. Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: towards advanced delivery of antibiotics10.1016/j.addr.2017.12.010 ↗
20. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections10.1016/j.ijantimicag.2014.02.009 ↗
21. MOF nanozyme mediated bacterial metabolic regulation to intervene MRSA antibiotic tolerance for enhanced antimicrobial efficacy10.1016/j.nantod.2025.102753 ↗
22. Nano drug delivery in intracellular bacterial infection treatments10.1016/j.biopha.2021.112609 ↗
23. Targeted drug delivery systems for eliminating intracellular bacteria10.1002/mabi.202200311 ↗
24. Cascade-targeting poly(amino acid) nanoparticles eliminate intracellular bacteria via on-site antibiotic delivery10.1002/adma.202109789 ↗
25. K+-responsive nanoparticles with charge reversal and gating synergistic effects for targeted intracellular bacteria eradication10.1021/acsnano.4c12542 ↗
26. Intracellular MRSA-targeted lipid-polymer hybrid nanoparticles for macrophage reprogramming and intracellular MRSA eradication10.1016/j.cej.2025.159665 ↗
27. Antibiotic-loaded lactoferrin nanoparticles as a platform for enhanced infection therapy through targeted elimination of intracellular bacteria
28. Dual-responsive nanogels with cascaded gentamicin release and lysosomal escape to combat intracellular small colony variants for peritonitis and sepsis therapies10.1002/adhm.202303671 ↗
29. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: A review of recent advances10.3389/fchem.2020.00286 ↗
30. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review10.1016/j.jare.2018.06.005 ↗
31. Current hurdles to the translation of nanomedicines from bench to the clinic10.1007/s13346-021-01024-2 ↗
32. Clinical applications and therapeutic potentials of advanced nanoparticles: a comprehensive review on completed human clinical trials10.3389/fnano.2024.1479993 ↗
33. Current trends and challenges in pharmacoeconomic aspects of nanocarriers as drug delivery systems for cancer treatment10.2147/IJN.S323831 ↗
34. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification
35. Carrier-free nanodrugs: from bench to bedside10.1021/acsnano.4c09027 ↗
36. Carrier-free nanomedicines: mechanisms of formation and biomedical applications10.1016/j.giant.2024.100256 ↗
37. Drug self-delivery systems for cancer therapy10.1016/j.biomaterials.2016.10.016 ↗
38. Advance progress in assembly mechanisms of carrier-free nanodrugs for cancer treatment10.3390/molecules28207065 ↗
39. Self-carrier nanodrugs with dual antibacterial agents to overcome tobramycin resistance in multidrug-resistant Staphylococcus aureus
40. Novel carrier-free nanomedicine for regulating macrophage phenotype to amplify anti-tumor photoimmunotherapy10.1002/smll.202505304 ↗
41. Sono-triggered biomimetically nanoantibiotics mediate precise sequential therapy of MRSA-induced lung infection10.1002/adma.202403612 ↗
42. Dual antibiotics-based pH-responsive carrier-free nanodrug against bacterial mixed infection for accelerated wound healing10.1002/adhm.202501845 ↗
43. Reaction-induced self-assembly of polymyxin mitigates cytotoxicity and reverses drug resistance10.1002/adma.202406156 ↗
44. Carrier-free nanomedicines for cancer treatment10.1016/j.pmatsci.2021.100919 ↗
45. Mannose-decorated solid-lipid nanoparticles for alveolar macrophage targeted delivery of rifampicin10.3390/pharmaceutics16030429 ↗
46. Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes10.1016/j.jconrel.2020.11.045 ↗
47. Producing anti-inflammatory macrophages by nanoparticle-triggered clustering of mannose receptors10.1016/j.biomaterials.2018.06.015 ↗
48. Advancing endosomal escape of polymeric nanoparticles: towards improved intracellular delivery10.1039/D4MH01781A ↗
49. Endolysosomal trapping of therapeutics and endosomal escape strategies10.1016/j.drudis.2024.104070 ↗
50. Bacterial growth-induced tobramycin smart release self-healing hydrogel for pseudomonas aeruginosa-infected burn wound healing10.1021/acsnano.2c05557 ↗
51. An improved phenol-sulfuric acid method for the determination of carbohydrates in the presence of persulfate10.1016/j.carbpol.2019.115332 ↗
52. Defect engineering of Cu2-xGaxO/PDINH nanomaterial for significantly improved photocatalytic antibacterial activities10.1016/j.nantod.2024.102230 ↗
53. pH switchable nanoplatform for in vivo persistent luminescence imaging and precise photothermal therapy of bacterial infection10.1002/adfm.201909042 ↗
54. Dual-targeted poly(amino acid) nanoparticles deliver drug combinations on-site: an intracellular synergistic strategy to eliminate intracellular bacteria10.1039/D3TB00125C ↗
55. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria10.1016/j.cmet.2015.01.008 ↗
56. Metabolite-enabled eradication of bacterial persisters by aminoglycosides10.1038/nature10069 ↗
57. A mini-review: Environmental and metabolic factors affecting aminoglycoside efficacy10.1007/s11274-022-03445-8 ↗
58. A membrane curvature modulated lipopeptide to broadly combat multidrug-resistant bacterial pneumonia with low resistance risk10.1021/acsnano.2c07251 ↗
59. Self-assembled copper-amino acid nanoleaves for targeted treatment of deep-seated bacterial infections via chemodynamic therapy and cuproptosis-like death10.1016/j.biomaterials.2025.123566 ↗
60. Fabrication and biological imaging application of AIE-active luminescent starch based nanoprobes10.1016/j.carbpol.2016.01.030 ↗
61. AIE-based nanoaggregate tracker: high-fidelity visualization of lysosomal movement and drug-escaping processes10.1039/D0SC04156D ↗
62. Corpse engulfment generates a molecular memory that primes the macrophage inflammatory response10.1016/j.cell.2016.04.049 ↗
63. Antimicrobial peptides loaded collagen nanosheets with enhanced antibacterial activity, corneal wound healing and M1 macrophage polarization in bacterial keratitis10.1016/j.compositesb.2024.111283 ↗
64. Pathogen-targeting biomineralized bacterial outer membrane vesicles for eradicating both intracellular and extracellular Staphylococcus aureus10.1016/j.jconrel.2025.113702 ↗
65. Seeking cells, targeting bacteria: a cascade-targeting bacteria-responsive nanosystem for combating intracellular bacterial infections10.1002/smll.202311967 ↗
66. Recyclable surfactant containing a dynamic covalent bond and relevant smart emulsions10.1039/D2GC01977A ↗
67. GSH/pH cascade-responsive nanoparticles eliminate methicillin-resistant Staphylococcus aureus biofilm via synergistic photo-chemo therapy10.1021/acsami.3c17198 ↗